Five Below Inc vs ResMed Inc. — how do they compare? Five Below Inc trades at $209.72 (market cap $11.25B), while ResMed Inc. trades at $227.51 (market cap $31.78B). The key difference: ResMed Inc. is far larger — about 2.8× Five Below Inc's market cap, and ResMed Inc. pays a 1.17% dividend while Five Below Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Five Below Inc for 46 Days and ResMed Inc. for 51 Days on average.
| FIVE | RMD | |
|---|---|---|
Market Cap | $11.25B | $31.78B |
Volume | 986,546 | 1,128,382 |
Sector | Consumer Cyclical | Health |
52-Week High | $262.72 | $277.88 |
52-Week Low | $138.49 | $182.82 |
Typical Hold Time | 46 Days | 51 Days |
Enterprise Value | $12.10B | $31.14B |
Dividend Yield | — | 1.17% |
Signals from Pluang's Aura AI — not financial advice
Five Below (FIVE) trades at $209.56, down 0.17% on the day, with a bearish technical signal despite bullish oscillators. The company shows strong profitability with 40.26% gross margins and 28.25% ROE, though net margins declined to 6.54% in 2025. Recent earnings beats and a raised 2026 outlook highlight growth momentum, supported by store expansion and digital initiatives. Cash flow improved significantly in 2025 with $152M net inflow after two years of negative flows.
The stock offers substantial upside to the $298.44 consensus target, with 60% analyst buy ratings and no sell recommendations. Key risks include premium valuation (P/E 18.32) and execution pressure amid consumer spending concerns. Growth catalysts include the $600M buyback and store revamp strategy, though technical resistance near $212 may limit near-term gains.
ResMed (RMD) trades at $225.98, up 2.4% today, with a bullish technical outlook supported by moving averages and strong fundamentals. The company reported revenue of $5.15B in 2025, with net income of $1.40B and robust margins. Recent earnings beats and a dividend announcement highlight operational strength, while analyst consensus leans positive with a $242.70 price target.
Outlook remains favorable due to consistent EPS growth and market share gains, though risks include competitive pressures and ongoing legal investigations. The stock offers growth potential from healthcare demand tailwinds, but investors should monitor execution against guidance and macroeconomic factors affecting medical device spending.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Five Below is a value-oriented retailer that operated 1,190 stores in the United States as of the end of fiscal 2021. Catering to teen and preteen consumers, stores feature a wide variety of merchandise, the vast majority of which is priced below $6. The assortment focuses on discretionary items in several categories, particularly leisure (such as sporting goods, toys, and electronics
Read more on FIVE →ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →